Stevanato Group S.p.A. STVN
Set alert
As of Nov 3, 2:17 PM ET
- YTD
- -28.13%
- 1 year
- -41.41%
- Open
- 15.94
- Prev close
- 19.74
- Mkt cap
- 3.95B
- Vol
- 3.38M
- Avg vol
- 394.27K
- EPS
- 0.57
- P/E
- 25.37
- Div yield
- 0.00%
More statistics
- Low
- 13.03
- High
- 15.58
- Forward P/E
- 23.99
- Beta
- 0.80
- Short ratio
- 3.04
- Inst. own
- 102.96%
- Dividend
- 0.06
- Ex-div date
- Jun 10, 2026
- Earnings
- Nov 3, 2026
- 50-d avg
- 20.58
- 200-d avg
- 18.10
- 1y target
- 24.84
5m chart
Built from the cached five-day intraday bars.
Events in this range
- Nov 3, 2026Earnings: —; estimate 0.1775; surprise —%
Signals (111)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 3, 11:00 AM | 3 hours ago |
| RSI: Oversold | Nov 3, 11:00 AM | 3 hours ago |
| MACD: Buy Signal | Nov 3, 10:35 AM | 3 hours ago |
| SMA: Bearish | Nov 3, 10:25 AM | 3 hours ago |
| SMA: Bullish | Nov 3, 10:20 AM | 3 hours ago |
| RSI: Oversold | Nov 3, 9:30 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 3:50 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 3:50 PM | 22 hours ago |
| MACD: Sell Signal | Nov 2, 3:50 PM | 22 hours ago |
| MACD: Buy Signal | Nov 2, 3:40 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 3:35 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 3:35 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 3:25 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 3:25 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 3:20 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 3:20 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 3:10 PM | 23 hours ago |
| MACD: Sell Signal | Nov 2, 3:10 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 2:55 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 2:50 PM | 23 hours ago |
Newest 20 of 111.
Key statistics
- Market cap
- 5.40B
- Enterprise value
- 5.66B
- Trailing P/E
- 34.73
- Forward P/E
- 23.99
- PEG ratio
- 1.38
- Price / sales
- 4.41
- Price / book
- 3.11
- EPS (TTM)
- 0.57
- Beta
- 0.80
- Dividend yield
- 0.32%
- Payout ratio
- 11.02%
- Profit margin
- 10.99%
- Revenue (TTM)
- 1.23B
- Revenue growth
- 7.80%
- Free cash flow
- -104.70M
- Total cash
- 79.14M
- Total debt
- 445.30M
- Return on equity
- 9.13%
- Shares outstanding
- 49.71M
- Short % of float
- 1.97%
- 50-day average
- 20.58
- 200-day average
- 18.10
Analyst view
Consensus: buy
- Target (low)
- 21.00
- Target (mean)
- 24.84
- Target (high)
- 32.00
- Strong buy2
- Buy7
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 0.1776.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | 0.1775 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | 0.1448 | 0.16 | +0.02 | +10.50% |
| May 7, 2026 | Mar 31, 2026 | 0.12 | 0.13 | +0.01 | +8.33% |
| Mar 4, 2026 | Dec 31, 2025 | 0.20 | 0.21 | +0.01 | +5.00% |
| Nov 6, 2025 | Sep 30, 2025 | 0.14 | 0.16 | +0.02 | +14.29% |
| Aug 5, 2025 | Jun 30, 2025 | 0.11 | 0.12 | +0.01 | +9.09% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | main | Neutral | Neutral |
| Jun 16, 2026 | TD Cowen | init | — | Buy |
| Mar 6, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Mar 5, 2026 | Citigroup | main | Buy | Buy |
| Mar 5, 2026 | Keybanc | main | Overweight | Overweight |
| Dec 2, 2025 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- Italy
- Website
- stevanatogroup.com
News
- Nasdaq Surges 1%; Pfizer Posts Upbeat Q3 Earnings
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Stevanato Group Q3 2026 Earnings Call Transcript
- Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates
- Stevanato Group continues to expect revenue in the range of €1.260 billion to €1.280 billion, adjusted EBITDA of €335.0 million to €345.2 million, and adjusted diluted EPS of €0.60 to €0.62.
- Stevanato Gr Q3 Adj. EPS $0.18 Beats $0.17 Estimate, Sales $375.303M Beat $363.840M Estimate
- Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
- Conestoga Small Cap Composite Q3 2026 Portfolio Activity
- Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
- Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update
Your note
Sign in to keep a note on STVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALACHANDRAN MADHAVEN | Director | Sale | Jun 14, 2026 | 69,458 |
| DAL LAGO MARCO | Chief Financial Officer | Sale | Aug 6, 2026 | 81,144 |
| FEDERICI WILLIAM J | Director | Sale | Jun 14, 2026 | 58,580 |
| FLYNN KAREN A | Director | Sale | Jun 14, 2026 | 5,757 |
| LIN SUE-JEAN | Director | Stock Award(Grant) | Jun 11, 2026 | 6,975 |
| MAGISTRETTI ELISABETTA | Director | Sale | Aug 6, 2026 | 2,930 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Conestoga Capital Advisors, LLC | 2.31% | 7,007,613 | 138.72M | Jun 29, 2026 |
| Neuberger Berman Group, LLC | 1.86% | 5,622,269 | 111.29M | Jun 29, 2026 |
| Times Square Capital Management, LLC | 1.15% | 3,474,641 | 68.78M | Jun 29, 2026 |
| Van Berkom & Associates Inc. | 0.98% | 2,969,220 | 58.78M | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 0.86% | 2,601,598 | 51.50M | Jun 29, 2026 |
| BAMCO Inc. | 0.82% | 2,494,871 | 49.39M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Conestoga Funds-Conestoga Small Cap Fund | 1.15% | 3,484,751 | 68.98M | Jun 29, 2026 |
| NEUBERGER BERMAN EQUITY FUNDS-Neuberger Genesis Fund | 1.00% | 3,041,141 | 60.20M | Sep 29, 2026 |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 0.56% | 1,681,429 | 33.28M | Jun 29, 2026 |
| Artisan Partners Funds Inc.-Artisan Small Cap Fund | 0.28% | 837,773 | 16.58M | Jun 29, 2026 |
| AMG Funds-AMG TimesSquare Mid Cap Growth Fund | 0.22% | 653,137 | 12.93M | Jun 29, 2026 |
| Conestoga Funds-Conestoga SMid Cap Fund | 0.20% | 596,192 | 11.80M | Jun 29, 2026 |